361 related articles for article (PubMed ID: 2991678)
1. Binding of a new opiate antagonist, nalmefene, to rat brain membranes.
Michel ME; Bolger G; Weissman BA
Methods Find Exp Clin Pharmacol; 1985 Apr; 7(4):175-7. PubMed ID: 2991678
[TBL] [Abstract][Full Text] [Related]
2. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
Tam SW; Liu-Chen LY
J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954
[TBL] [Abstract][Full Text] [Related]
3. Multiple opiate binding sites in the central nervous system of the rabbit. Large predominance of a mu subtype in the cerebellum and characterization of a kappa subtype in the thalamus.
Meunier JC; Kouakou Y; Puget A; Moisand C
Mol Pharmacol; 1983 Jul; 24(1):23-9. PubMed ID: 6306437
[TBL] [Abstract][Full Text] [Related]
4. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
5. beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.
Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW
J Pharmacol Exp Ther; 1988 Nov; 247(2):405-16. PubMed ID: 2846819
[TBL] [Abstract][Full Text] [Related]
6. Solubilization and preliminary characterization of mu and kappa opiate receptor subtypes from rat brain.
Chow T; Zukin RS
Mol Pharmacol; 1983 Sep; 24(2):203-12. PubMed ID: 6310362
[TBL] [Abstract][Full Text] [Related]
7. Affinities of opiate agonists and antagonists for the enkephalin receptors of rat brain.
Wong DT; Horng JS
Res Commun Chem Pathol Pharmacol; 1977 Apr; 16(4):749-52. PubMed ID: 193169
[TBL] [Abstract][Full Text] [Related]
8. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.
Hahn EF; Nishimura S; Goodman RR; Pasternak GW
J Pharmacol Exp Ther; 1985 Dec; 235(3):839-45. PubMed ID: 2416909
[TBL] [Abstract][Full Text] [Related]
9. Covalent labeling of mu opioid binding site by [3H]beta-funaltrexamine.
Liu-Chen LY; Phillips CA
Mol Pharmacol; 1987 Sep; 32(3):321-9. PubMed ID: 2823089
[TBL] [Abstract][Full Text] [Related]
10. Antagonist-induced up-regulation of the putative epsilon opioid receptor in rat brain: comparison with kappa, mu and delta opioid receptors.
Giordano AL; Nock B; Cicero TJ
J Pharmacol Exp Ther; 1990 Nov; 255(2):536-40. PubMed ID: 2173747
[TBL] [Abstract][Full Text] [Related]
11. Modulation of rat brain opioid receptors by cannabinoids.
Vaysse PJ; Gardner EL; Zukin RS
J Pharmacol Exp Ther; 1987 May; 241(2):534-9. PubMed ID: 3033219
[TBL] [Abstract][Full Text] [Related]
12. Cation and guanine nucleotide effects on ligand binding properties of mu and delta opioid receptors in rat brain membranes.
Benyhe S; Szücs M; Varga E; Simon J; Borsodi A; Wollemann M
Acta Biochim Biophys Hung; 1989; 24(1-2):69-81. PubMed ID: 2558475
[TBL] [Abstract][Full Text] [Related]
13. Naloxonazine effects on the interaction of enkephalin analogs with mu-1, mu and delta opioid binding sites in rat brain membranes.
Cruciani RA; Lutz RA; Munson PJ; Rodbard D
J Pharmacol Exp Ther; 1987 Jul; 242(1):15-20. PubMed ID: 3039108
[TBL] [Abstract][Full Text] [Related]
14. Arachidonic acid modulation of [3H]naloxone specific binding to rat brain opioid receptors.
Oktem HA; Apaydin S
Neurobiology (Bp); 1998; 6(3):323-32. PubMed ID: 9778651
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
[TBL] [Abstract][Full Text] [Related]
16. Sodium regulation of agonist binding at opioid receptors. I. Effects of sodium replacement on binding at mu- and delta-type receptors in 7315c and NG108-15 cells and cell membranes.
Puttfarcken P; Werling LL; Brown SR; Cote TE; Cox BM
Mol Pharmacol; 1986 Aug; 30(2):81-9. PubMed ID: 3016503
[TBL] [Abstract][Full Text] [Related]
17. Delta and mu opioid receptors from the brain of a urodele amphibian, the rough-skinned newt Taricha granulosa: cloning, heterologous expression, and pharmacological characterization.
Bradford CS; Walthers EA; Stanley DJ; Baugh MM; Moore FL
Gen Comp Endocrinol; 2006 May; 146(3):275-90. PubMed ID: 16375901
[TBL] [Abstract][Full Text] [Related]
18. Adrenal medullary opiate receptors. Pharmacological characterization in bovine adrenal medulla and a human pheochromocytoma.
Castanas E; Giraud P; Audigier Y; Drissi R; Boudouresque F; Conte-Devolx B; Oliver C
Mol Pharmacol; 1984 Jan; 25(1):38-45. PubMed ID: 6323951
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical and subtype-specific effects of opiate antagonists on the expression of opioid receptors in rat brain cultures.
Barg J; Levy R; Simantov R
J Neurosci Res; 1989 Mar; 22(3):322-30. PubMed ID: 2540341
[TBL] [Abstract][Full Text] [Related]
20. Receptor binding of [3H]naloxone benzoylhydrazone: a reversible kappa and slowly dissociable mu opiate.
Price M; Gistrak MA; Itzhak Y; Hahn EF; Pasternak GW
Mol Pharmacol; 1989 Jan; 35(1):67-74. PubMed ID: 2536470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
